Your browser doesn't support javascript.
loading
YAP1 is essential for malignant mesothelioma tumor maintenance.
Calvet, Loreley; Dos-Santos, Odette; Spanakis, Emmanuel; Jean-Baptiste, Véronique; Le Bail, Jean-Christophe; Buzy, Armelle; Paul, Pascal; Henry, Christophe; Valence, Sandrine; Dib, Colette; Pollard, Jack; Sidhu, Sukhvinder; Moll, Jürgen; Debussche, Laurent; Valtingojer, Iris.
Afiliación
  • Calvet L; Department of Oncology, In Vivo Pharmacology, Sanofi Research Center, Vitry-sur-Seine, France. loreley.calvet@sanofi.com.
  • Dos-Santos O; Department of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
  • Spanakis E; Department of Oncology, Precision Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
  • Jean-Baptiste V; Department of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
  • Le Bail JC; Department of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
  • Buzy A; Department of Translational Sciences, Sanofi Research Center, Chilly Mazarin, France.
  • Paul P; Department of Translational Sciences, Sanofi Research Center, Chilly Mazarin, France.
  • Henry C; Department of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
  • Valence S; Department of Oncology, Precision Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
  • Dib C; Department of Oncology, Precision Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
  • Pollard J; Department of Oncology, Precision Oncology, Sanofi Research Center, Cambridge, USA.
  • Sidhu S; Department of Oncology, In Vivo Pharmacology, Sanofi Research Center, Vitry-sur-Seine, France.
  • Moll J; Department of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
  • Debussche L; Department of Oncology, In Vivo Pharmacology, Sanofi Research Center, Vitry-sur-Seine, France.
  • Valtingojer I; Department of Oncology, Molecular Oncology, Sanofi Research Center, Vitry-sur-Seine, France.
BMC Cancer ; 22(1): 639, 2022 Jun 10.
Article en En | MEDLINE | ID: mdl-35689194
Malignant pleural mesothelioma, a tumor arising from the membrane covering the lungs and the inner side of the ribs, is a cancer in which genetic alterations of genes encoding proteins that act on or are part of the Hippo-YAP1 signaling pathway are frequent. Dysfunctional Hippo signaling may result in aberrant activation of the transcriptional coactivator protein YAP1, which binds to and activates transcription factors of the TEAD family. Recent studies have associated elevated YAP1 protein activity with a poor prognosis of malignant mesothelioma and its resistance to current therapies, but its role in tumor maintenance is unclear. In this study, we investigate the dependence of malignant mesothelioma on YAP1 signaling to maintain fully established tumors in vivo. We show that downregulation of YAP1 in a dysfunctional Hippo genetic background results in the inhibition of YAP1/TEAD-dependent gene expression, the induction of apoptosis, and the inhibition of tumor cell growth in vitro. The conditional downregulation of YAP1 in established tumor xenografts leads to the inhibition of YAP1-dependent gene transcription and eventually tumor regression. This effect is only seen in the YAP1-activated MSTO-211H mesothelioma xenograft model, but not in the Hippo-independent HCT116 colon cancer xenograft model. Our data demonstrate that, in the context of a Hippo pathway mutated background, YAP1 activity alone is enough to maintain the growth of established tumors in vivo, thus validating the concept of inhibiting the activated YAP1-TEAD complex for the treatment of malignant pleural mesothelioma patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mesotelioma Maligno / Mesotelioma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mesotelioma Maligno / Mesotelioma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido